Colfax

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Wilmington, DE, April 05, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the “Separation”) of its fabrication technology business into an independent, publicly traded company, ESAB Corporation (“ESAB”) (NYSE: ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued and outstanding shares of Enovis common stock at a one-for-three ratio.

Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation

Enovis Corp

ESAB Corp

PROG Holdings

S&P Global

NEW YORK , March 30, 2022 /PRNewswire/ -- ESAB Corp. (NYSE: ESAB) will be added to the S&P MidCap 400 effective prior to the opening of trading on Tuesday, April 5. Effective prior to the opening of trading on Wednesday, April 6, S&P MidCap 400 constituent PROG Holdings Inc. (NYSE: PRG) will replace Fiesta Restaurant Group Inc. (NASD: FRGI) in the S&P SmallCap 600.

ESAB Set to Join S&P MidCap 400; PROG Holdings to Join S&P SmallCap 600

Wilmington, DE, March 28, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company which will renamed Enovis Corporation (“Enovis”) following the expected April 4, 2022 consummation of the Company's previously announced spin-off of its fabrication technology business (the “Separation"), which will operate as ESAB Corporation (“ESAB”) after the Separation, today announced the future composition of the full ESAB Board of Directors (the “Board”).

Colfax Announces Board of Directors for Post-Spinoff ESAB

Colfax (CFX) reported earnings 30 days ago. What's next for the stock?

Why Is Colfax (CFX) Down 4.2% Since Last Earnings Report?

Colfax Corp's (NYSE: CFX) price target has been lowered to $52 (an upside of 41%) from $60 by KeyBanc analyst Jeffrey Hammond, following ESAB/Enovis's 2022 Investor Day to reflect broadly lower peer multiples. The analyst maintained an Overweight rating on CFX.

KeyBanc, Morgan Stanley Slash Price Target On Colfax

Wilmington DE,, March 14, 2022 (GLOBE NEWSWIRE) -- —Colfax Corporation (“Colfax”) (NYSE: CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of the outstanding common stock of ESAB Corporation (“ESAB”) to Colfax shareholders of record as of the close of business on March 22, 2022 (the “Record Date”), and (b) that the previously announced reverse stock split of all issued and outstanding shares of Colfax Common Stock will be effected at a one-for-three ratio (the “Reverse Stock Split”) following the distribution of the ESAB shares. The distribution is expected to be payable after the market close on April 4, 2022 (“Distribution Date”). As a result of the distribution, Colfax shareholders will receive one share of ESAB common stock for every three shares of Colfax common stock they hold on the Record Date (pre-Reverse Stock Split ratio). Immediately following the distribution, Colfax will retain 10% of the outstanding shares of ESAB common stock, which Colfax intends to divest within 12 months after the separation in a tax-efficient exchange for its outstanding debt.

Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation

Wilmington DE,, March 11, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced the future composition of the Board of Directors (the “Board”) of the Company, which will be renamed Enovis Corporation (“Enovis”) upon the consummation of the Company's previously announced spin-off (the "Separation”) of its existing fabrication technology business, which will operate as ESAB Corporation.

Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company

Wilmington, DE, March 07, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it had given notice of its intention to redeem €350 million principal amount representing of its outstanding 3.250% Senior Notes due 2025 (ISIN Numbers XS1599407217, XS1599406839) (the “2025 Notes”) and $300 million principal amount representing all of its outstanding 6.375% Senior Notes due 2026 (CUSIP Numbers 15723RAC8, U1581TAB4) (the “2026 Notes” and, together with the 2025 Notes, the “Notes”) on April 7, 2022 (the “Redemption Date”), and is conditioned upon the receipt of aggregate gross proceeds from the completion of the intended separation of Colfax's fabrication technology and specialty medication technology businesses (the “Condition”), which Condition the Company may waive at its discretion. The Company may also delay, at its discretion, the Redemption Date to any series of Notes until such time as the Condition has been satisfied, or the redemption of such series of Notes may be rescinded in the event that the Condition has not been satisfied by the Redemption Date.

Colfax Announces Conditional Redemption of its 3.250% Senior Notes due 2025 and its 6.375% Senior Notes due 2026

Colfax's (CFX) fourth-quarter 2021 net sales increase 23.6% year over year on impressive performance across its segments.

Colfax (CFX) Q4 Earnings & Revenues Surpass Estimates, Up Y/Y

Colfax Corporation (CFX) CEO Matt Trerotola on Q4 2021 Results - Earnings Call Transcript

Colfax (CFX) delivered earnings and revenue surprises of 3.51% and 2.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Beats Q4 Earnings and Revenue Estimates

DALLAS--(BUSINESS WIRE)-- #acfas--DJO®, a leading global provider of medical technologies, announced it will showcase their growing Foot & Ankle offerings at ACFAS 2022.

DJO® Showcases Growing Foot & Ankle Portfolio at ACFAS Scientific Conference

Wilmington, DE, Feb. 22, 2022 (GLOBE NEWSWIRE) --  Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the fourth quarter and fiscal year 2021 and provided additional updates.

Colfax Corporation Announces Fourth Quarter and Full Year 2021 Results

Colfax (CFX) is poised to benefit from its exposure in diverse end markets, acquired assets and solid demand for its products. However, rising costs and high debt levels remain concerns.

Colfax (CFX) Exhibits Strong Prospects, Headwinds Persist

Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Colfax (CFX) Earnings Expected to Grow: Should You Buy?

Wilmington DE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter and fiscal year 2021 on the morning of Tuesday, February 22, 2022.

Colfax Schedules Fourth Quarter and Fiscal Year 2021 Earnings Release and Conference Call

Colfax (CFX) benefits from solid product offerings and focus on innovation, healthy demand and acquisition synergies. Cost inflation and supply-chain woes are concerning.

Colfax's (CFX) Product Strength Aids Amid Cost & Supply Woes

Wilmington, DE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, announced today that it will be presenting at the J.P. Morgan Healthcare Conference on January 12, at 3:00 pm (EST).  A live presentation of this event will be available via Colfax's website at  www.colfaxcorp.com  under the “Investors” section. Replays will also be available on the Company's website following the event.

Colfax to Present at the 40th Annual JP Morgan Healthcare Conference

Lincoln Electric Hlds

Loop Capital analyst Chris Dankert initiated coverage of two Machinery companies.

Loop Capital Is Bullish On Lincoln Electric; Initiates Colfax With Hold

WILMINGTON, DE, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it plans to hold a special meeting of stockholders to seek approval for an amendment to the Company's Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect, at the discretion of the Board of Directors, (i) a reverse stock split of the Company's common stock, par value $0.001 per share (the “Common Stock”), at one of three reverse stock split ratios, one-for-two, one-for-three or one-for-four, with the exact ratio to be determined by the Board of Directors of the Company at a later date, and (ii) if and when the reverse stock split is effected, a corresponding reduction in the number of authorized shares of our Common Stock by the selected reverse stock split ratio.

Colfax Announces Plans for Reverse Stock Split

Airbnb

Affirm

Confluent

Colfax Corp - Units

Dell Technologies

DocuSign

Expedia

Five9

Illumina

Lemonade

MongoDB

monday.com

Moderna

Netflix

ServiceNow

Okta

PayPal

Take-Two Interactive Software

Twilio

Upstart Holdings

VMware

Zoom Video

Sharp sell-offs can reveal great stock ideas if you surface the right stocks that contrary to the market action close positive. When picking names that close in the green, make sure they are well known and of a higher market cap. They tend to have sustainable rallies when they turn around.

Forget The Covid Apocalypse, Focus On Stocks That Closed Green After Friday's Monster Sell Off

Colfax Corporation's (CFX) CEO Matt Trerotola on Q3 2021 Results - Earnings Call Transcript

Colfax's (CFX) Q3 earnings reflect the impacts of improved sales, margin expansion, supply-chain woes and logistics issues. For 2021, it lowers earnings projections on high taxes and pandemic woes.

Colfax (CFX) Meets Earnings Estimates in Q3, Lowers View

Colfax (CFX) delivered earnings and revenue surprises of 0.00% and 1.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Q3 Earnings Match Estimates

Colfax Corp (NYSE: CFX) reported third-quarter sales growth of 20% year-over-year to $965.89 million, +15% on an organic sales-per-day basis, beating the consensus of $958.430 million. Adjusted EPS improved to $0.54 from $0.41 in 3Q20, beating the consensus of $0.53.

News for Colfax Stock (CFX)